Burkes Robert M, Panos Ralph J, Borchers Michael T
University of Cincinnati College of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine.
Cincinnati Veterans' Affairs Medical Center, Cincinnati, Ohio, USA.
Curr Opin Pulm Med. 2021 Mar 1;27(2):120-124. doi: 10.1097/MCP.0000000000000751.
This review discusses emerging therapies directed at chronic obstructive pulmonary disease (COPD) endotypes and pathobiological processes that manifest as the disease.
Specific endotypes have been targeted in COPD. These include eosinophilic inflammation, overproduction of interleukin-17, chronic bronchitis and altered nature of mucous, and chronic infection. Therapies exactly directed at the cause of these endotypes or their resultant clinical findings have been assessed. Although some intermediate outcomes have seemed promising, there have been no findings that shift the paradigm of COPD therapy.
Basic and clinical scientists continue to define endotypes that may be directly addressed with therapeutics. As of the time of this up-to-date review, there is yet to be an endotype-directed therapy to demonstrate great clinical effect.
本综述讨论针对慢性阻塞性肺疾病（COPD）内型以及表现为该疾病的病理生物学过程的新兴疗法。
COPD中已针对特定内型进行研究。这些内型包括嗜酸性粒细胞炎症、白细胞介素-17过度产生、慢性支气管炎和黏液性质改变以及慢性感染。已经评估了针对这些内型病因或其所致临床结果的疗法。尽管一些中间结果看起来很有前景，但尚未有能改变COPD治疗模式的发现。
基础科学家和临床科学家继续确定可能通过治疗直接解决的内型。截至本次最新综述时，尚未有一种以内型为导向的疗法能显示出显著的临床效果。
